Your Article Summary
See Latest ArticlesCaspofungin for the treatment of candidaemia in patients with haematological malignancies
Clinical Microbiology and Infection, 06/29/09
Pagano L et al. - In a study to evaluate the efficacy of caspofungin in neutropenic pts with haematological malignancies (HM) and candidaemia, results suggest that treatment of candidaemia with caspofungin in neutropenic HM was efficacious, as it is in non-haematological subgroups.
Methods- This study was prospectively conducted in 11 haematology divisions over a 2-yr period to evaluate the efficacy of caspofungin in 24 neutropenic pts with haematological malignancies (HM) and candidaemia.
- Pts had received chemotherapy for HM and were neutropenic (PNN < 0.5 x 109/L) for a median of 12 days (2–41) before candidaemia.
- Pts received caspofungin for a median duration of 12 days, obtaining a favourable overall response of 58%.
- At 30 days, 11 pts had died (46%); candidaemia was responsible for mortality in 6 pts (25%).
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Novel Therapies for Pemphigus Vulgaris: An Overview
Drugs & Aging, 09/21/09
Antithrombotic medication for stroke prevention
Expert Review of Cardiovascular Therapy , 10/20/09
Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: Clinicopathological features of 24 patients
Journal of Rheumatology, 11/09/09
Today in Infectious Disease...keeping you current
Receive free subspecialty "5-minute updates" via email
HIV-Specific Health Care Utilization and Mortality among Tuberculosis/HIV Coinfected Persons
AIDS Patient Care and STDs, 10/06/09
Influenza Management Guide 2009-2010
American Family Physician, 11/18/09
Bed bugs - What the GP needs to know
Australian Family Physician, 11/09/09